Aptimmune Biologics Raises $2.75M of Series A

Aptimmune Biologics, a mucosal vaccine company developing novel pig vaccines for PRRSV and influenza virus, received $2. $75 million in funding from Arsenal Capital Management, Fox Ventures LLC, and Midwest Angel Investors Group.

‘PRRSV and influenza virus are a growing threat to the health of pigs worldwide. The combined annual economic impact on the U Oh, S The pig industry alone is over $1 $4 billion Our new portfolio of vaccines will change the management of these diseases, significantly improve the health of pigs and increase the productivity of producers’

‘PRRSV and influenza virus are a growing threat to the health of pigs worldwide. The combined annual economic impact on the U Oh, S The pig industry alone is over $1 $4 billion Our new portfolio of vaccines will change the management of these diseases, significantly improve the health and productivity of pigs,” said Dr. Federico Zuckermann, founder and Chief Scientific Officer of Aptimmune

Dr. Dr. Zuckermann is a leading pig immunologist, professor at the University of Illinois at Urbana-Champaign, and inventor of patented vaccine technologies marketed by Aptimmune. Over the last 30 years, he has dedicated himself to a better understanding of PRRSV and other swine diseases that plague producers.

Aaron Gilbertie, who joined the company as CEO weeks prior to funding, will lead the company through pipeline development, product registration and commercialization of Aptimmune’s revolutionary vaccines.

‘This funding puts Aptimmune in a position to accelerate its mucosal vaccine candidates through development and product registration. Our vaccines will fundamentally change the way we think about and practice pig vaccination,” said Gilbertie.

He notes that the new product offerings of Aptimmune are based on a strong and extensive portfolio of intellectual property Arsenal Capital Management (ACM) Louis-based venture capital group with investments in biotechnology, medical technology, IT and consumer goods

Aptimmune joins other major ACM biotech investments, including Kypha, KEW Group and Appistry.

‘We have been monitoring the progress of Aptimmune through our relationship with Common Place Holdings. I am pleased that this investment validates our approach to early investment in promising companies and provides additional support as growth demands,” said Pete Reinecke, Managing Director of Arsenal.

ACM is the sole external source of funding for the Common Place Holdings (CPH) seed fund. CPH was an AA investor and business advisor to the Aptimmune Series

Fox Ventures is an investment firm based in Champaign that assists companies with consulting, networking, recruitment and financial resources.

Aptimmune is based in the technology business incubator of EntepriseWorks at the University of Illinois, Urbana-Champaign. Located in the heart of the University of Illinois Research Park, EnterpriseWorks’ mission is to launch, support and advance science-based start-ups that commercialize disruptive technologies. EnterpriseWorks incubated companies have raised more than $870 in venture capital and angel investment since 2003. A 2015 Brookings Institute risk capital flow study has shown that Champaign-Urbana ranks among the top 20 meters of annual venture capital first-time per-capita funding, with 3 metres. 2 times the national average;

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Aptimmune%20Biologics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co